Raptor Pharmaceutical Inc. Release: PROCYSBI® Receives Positive Opinion for Orphan Drug Exclusivity From the EU Committee for Orphan Medicinal Products

Published: Jul 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NOVATO, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan Medicinal Products (COMP) recommending orphan drug exclusivity for PROCYSBI® (mercaptamine) gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis. Final adoption of the opinions on drug approval and orphan exclusivity are expected from the European Commission in the coming months.

Help employers find you! Check out all the jobs and post your resume.

Back to news